Deprenyl Animal Health, Inc. v. University of Toronto Innovations Foundation

161 F. Supp. 2d 1272, 2001 U.S. Dist. LEXIS 12927, 2001 WL 968264
CourtDistrict Court, D. Kansas
DecidedAugust 10, 2001
DocketCIV. A. 00-2234-CM
StatusPublished
Cited by1 cases

This text of 161 F. Supp. 2d 1272 (Deprenyl Animal Health, Inc. v. University of Toronto Innovations Foundation) is published on Counsel Stack Legal Research, covering District Court, D. Kansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Deprenyl Animal Health, Inc. v. University of Toronto Innovations Foundation, 161 F. Supp. 2d 1272, 2001 U.S. Dist. LEXIS 12927, 2001 WL 968264 (D. Kan. 2001).

Opinion

MEMORANDUM AND ORDER

MURGUIA, District Judge.

This lawsuit is a declaratory judgment action filed by plaintiff Deprenyl Animal Health, Inc. against defendant The University of Toronto Innovations Foundation involving a dispute over a patent license agreement and an underlying United States patent. This matter is before the court on defendant’s motion to dismiss for lack of personal jurisdiction or, in the alternative, to dismiss pending binding arbitration (Doc. 19).

I. Facts

Plaintiff is a corporation organized under the laws of Louisiana and having its principal place of business in Overland Park, Kansas. Plaintiff is a subsidiary of Draxis Health Inc. (“Draxis”), a Canadian corporation headquartered in Ontario, Canada. Plaintiff was incorporated to make use of a chemical compound known as L-Deprenyl in the animal market. Plaintiffs product is now sold under the trademark Anipryl® by Pfizer, Inc., who is licensed under the '449 patent.

Defendant is a corporation organized under the laws of Canada and having its offices in Toronto, Canada. Defendant is a technical licensing company founded by the University of Toronto to assist in commercial exploitation of inventions made by University of Toronto academic researchers. Defendant does not own or operate any offices or facilities in Kansas, nor does defendant employ any person or representative in Kansas. Defendant has never sold or advertised any products in Kansas.

In 1991, plaintiff approached defendant for a license under patent applications owned by defendant. The following year, plaintiff and defendant entered into a license agreement for technology that later matured into United States Patent 5,767,-164 (“the '164 patent”) held by defendant. Pursuant to the terms of the license agreement, defendant granted plaintiff an exclusive license to make, use, or sell the “licensed product.”

The essential terms of the license agreement initially were negotiated between Edward Kenney, president of defendant corporation, and James Doherty, president of Draxis, 1 both of whom were located in Toronto. The negotiations culminated in a letter of intent written to Mr. Kenney from Mr. Doherty. Plaintiff contends that, at this time, Draxis was only a minority shareholder of plaintiff and that Draxis had no involvement in the negotiation of the agreement.

With regard to the specific terms of the license agreement, plaintiff and defendant *1275 entered into a course of dealings whereby telephone and mail contact regularly were made between Mr. Kenney and David Stevens, president of plaintiff corporation, in Kansas. Plaintiff claims that Mr. Kenney traveled to Kansas in 1991 to negotiate the license agreement, but defendant asserts that Mr. Kenney does not recall this particular visit. In any event, on May 21, 1992, Mr. Kenny signed the license agreement in Toronto on behalf of defendant, and the following day, Mr. Stevens signed the license agreement in Overland Park on behalf of plaintiff.

Pursuant to the terms of the license agreement, defendant kept plaintiff informed as to the status of ongoing patent prosecution, which included sending copies of patent applications and patent office correspondence to plaintiff in Kansas for review and comment. Moreover, defendant was paid license fees directly by plaintiff from Kansas. The license agreement, however, states that all payments are to be made to defendant in Canadian dollars and that the agreement is to be construed in accordance with Canadian law. In 1994, Mr. Kenney traveled to Overland Park to discuss with Mr. Stevens a compromise regarding a dispute over plaintiffs performance under the license agreement. After the meeting, plaintiff and defendant eventually executed an amendment to the licensing agreement. Mr. Stevens executed the amendment in Kansas on behalf of plaintiff.

In December 1998, Draxis issued a press release announcing that it had obtained FDA approval for the sale of Anipryl for the treatment of canine cognitive dysfunction. In February 1999, defendant sent notice to plaintiff that any sales of Anipryl would be subject to the royalty provisions of the license agreement. The notice letter was sent to plaintiff in Kansas at the address stated in the license agreement. Defendant received a response from plaintiffs president on letterhead indicating that the response came from Ontario. All further communications from defendant to plaintiff were sent to plaintiffs Canadian office, and all responsive letters to defendant were received from plaintiffs Canadian office.

II. Discussion

Before a federal court can assert personal jurisdiction over a defendant in a federal question case, the court must determine that the exercise of jurisdiction comports with due process and that an applicable statute potentially confers jurisdiction by authorizing service of process. Peay v. BellSouth Med. Assistance Plan, 205 F.3d 1206, 1209 (10th Cir.2000). The Kansas long-arm statute is construed liberally to allow jurisdiction to the full extent permitted by due process; therefore, the court proceeds directly to the constitutional issue. Federated Rural Elec. Ins. Corp. v. Kootenai Elec. Coop., 17 F.3d 1302, 1305 (10th Cir.1994).

Under the due process analysis, the “constitutional touchstone” is “whether the defendant purposely established 'minimum contacts’ in the forum state.” Burger King Corp. v. Rudzewicz, 471 U.S. 462, 474, 105 S.Ct. 2174, 85 L.Ed.2d 528 (1985) (quoting Int’l Shoe Co. v. Washington, 326 U.S. 310, 316, 66 S.Ct. 154, 90 L.Ed. 95 (1945)). There must be some act by which the nonresident party purposefully avails itself of the privilege of conducting activities in the forum state. Hanson v. Denckla, 357 U.S. 235, 253, 78 S.Ct. 1228, 2 L.Ed.2d 1283 (1958). The purposeful availment requirement ensures that a defendant will not be sued in a foreign jurisdiction solely as a result of the unilateral activity of another party. Burger King, 471 U.S. at 475, 105 S.Ct. 2174.

Consistent with due process, specific jurisdiction may be conferred over a *1276 nonresident defendant where the court’s exercise of jurisdiction directly arises from a defendant’s forum related activities. To determine whether specific jurisdiction is appropriate, the court must first decide whether the defendant has such minimum contacts within the forum state “that he should reasonably anticipate being haled into court there.” World-Wide Volkswagen Corp. v. Woodson, 444 U.S. 286, 297, 100 S.Ct. 559 (1979).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
161 F. Supp. 2d 1272, 2001 U.S. Dist. LEXIS 12927, 2001 WL 968264, Counsel Stack Legal Research, https://law.counselstack.com/opinion/deprenyl-animal-health-inc-v-university-of-toronto-innovations-ksd-2001.